Qiagen logo Key Points Qiagen beat its outlook for 2025, reporting full-year net sales of $2.09 billion (+5% CER) and adjusted EPS of $2.40, with Q4 net sales of $540 million (+1% CER) and adjusted EPS of $0.62. The company’s five “growth pillars” generated $1.49 billion in 2025 (up 8% CER) — led by QIAstat‑Dx, QuantiFERON, QIAcuity, Sample Technologies and QDI — and management says this keeps Qiagen on track for at least $2 billion of combined growth‑pillar sales by 2028, aided by the Parse Bioscienc ...

Qiagen (NYSE:QGEN) Q4 2025 Earnings call February 05, 2026 09:30 AM ET Company ParticipantsDaniel Wendorff - VP and Head of Investor RelationsRoland Sackers - CFOThierry Bernard - CEOConference Call ParticipantsAisyah Noor - AnalystCasey Woodring - AnalystDan Brennan - AnalystDoug Schenkel - AnalystHarry Gillis - AnalystJack Meehan - AnalystKavya Deshpande - AnalystMichael Ryskin - AnalystOdysseas Manesiotis - AnalystTycho Peterson - AnalystOperatorLadies and gentlemen, thank you for standing by. I am Katie ...

Qiagen (NYSE:QGEN) Q4 2025 Earnings call February 05, 2026 09:30 AM ET Company ParticipantsDaniel Wendorff - VP and Head of Investor RelationsRoland Sackers - CFOThierry Bernard - CEOConference Call ParticipantsAisyah Noor - AnalystCasey Woodring - AnalystDan Brennan - AnalystDoug Schenkel - AnalystHarry Gillis - AnalystJack Meehan - AnalystKavya Deshpande - AnalystMichael Ryskin - AnalystOdysseas Manesiotis - AnalystTycho Peterson - AnalystOperatorLadies and gentlemen, thank you for standing by. I am Katie ...

Qiagen (NYSE:QGEN) Q4 2025 Earnings call February 05, 2026 09:30 AM ET Speaker7Ladies and gentlemen, thank you for standing by. I am Katie, your call operator. Welcome, and thank you for joining QIAGEN's fourth quarter 2025 earnings conference call webcast. At this time, all participants are in listen-only mode. Please be advised this call is being recorded at QIAGEN's request and will be made available on their internet site. The prepared remarks will be followed by a question-and-answer session. If you wo ...

Q4 and FY 2025 results Continuously delivering solid profitable growth February 4, 2026 Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "pl ...

Qiagen FY Conference Summary Company Overview - **Company**: Qiagen (NYSE: QGEN) - **Industry**: Life Sciences Tools and Diagnostics - **Market Position**: Qiagen has been developing molecular solutions for over 40 years, focusing on PCR, digital PCR, and next-generation sequencing, serving over 500,000 customers globally with a revenue of $2 billion, primarily from recurring consumables [3][4] Core Business Highlights - **Balanced Revenue Sources**: Over 50% of revenues come from the Americas, with significant contributions from Europe, the Middle East, Africa, and emerging markets [4] - **Growth Strategy**: Qiagen aims for a 7% CAGR through 2028, targeting $2 billion in revenues from key growth pillars and maintaining a 31% EBIT margin [6][7] - **Shareholder Returns**: Commitment to return at least $1 billion to shareholders, with recent share buybacks totaling $500 million [8][21] Financial Performance and Guidance - **2025 Performance**: Anticipated core growth of 5%-6% and EPS of $2.38, with operational execution on track [9] - **2026 Outlook**: Expected revenue growth of 5%-7%, with Parse Biosciences contributing approximately $40 million [24] Product Development and Innovations - **Sample Technology Leadership**: Qiagen is focusing on enhancing sample technology, with new instruments like QIAsymphony Connect and QIAmini set to launch [15][16] - **Digital PCR Growth**: The digital PCR market is expected to grow at 15%-20%, with Qiagen leading in placements and offering unique companion diagnostic solutions [25][26] - **QuantiFERON and Syndromic Testing**: QuantiFERON continues to show double-digit growth, with a target of $600 million in revenues by 2028. QIAstat is positioned as a solid number two in syndromic testing, with a target of $200 million by 2028 [10][31][32] Market Dynamics and Competitive Landscape - **Digital PCR Market**: Qiagen is competing with established players like Bio-Rad and Thermo Fisher, with a focus on expanding its assay offerings [25][26] - **QuantiFERON Competition**: Qiagen maintains a competitive edge through continuous investment in technology and partnerships, despite the presence of competitors [30] - **Syndromic Testing Market**: QIAstat is expected to grow with new panel approvals and a strong installed base, targeting unmet medical needs [31][32] Research and Development Focus - **Investment in R&D**: Qiagen allocates 9%-10% of revenues to R&D, focusing on automation and high-value applications [11][14] - **AI Integration**: The company is leveraging AI across various dimensions, including sales, marketing, and manufacturing, to enhance operational efficiency [19][20] M&A Strategy - **Acquisition Criteria**: Qiagen focuses on bolt-on acquisitions that are synergistic, immediately accretive to sales, and financially beneficial within two to three years [18][40] - **Recent Acquisitions**: The acquisition of Parse Biosciences and Genoox enhances Qiagen's capabilities in sample technology and bioinformatics [18][19] Conclusion - **Future Outlook**: Qiagen is optimistic about market recovery in the second half of 2026, continued growth in digital PCR, and the impact of new product launches in sample technology [41][42]

Financial Data and Key Metrics Changes - The company reported a strong performance with a growth rate of 7% in Q1 and 6% in Q2, outperforming the industry [2] - A $500 million share buyback was announced to be executed early next year, increasing from previous years' buybacks of $300 million [3] Business Line Data and Key Metrics Changes - The sample prep business showed improvement, with a growth of 3% in Q3, recovering from slight negatives in Q1 and positives in Q2 [17] - The consumables business, which constitutes 80-85% of sample prep, demonstrated resilience during market volatility [17] - Parse Biosciences is expected to generate around $20 million in revenues for 2024, with projections of $60 million in subsequent years, indicating strong growth potential [9] Market Data and Key Metrics Changes - The liquid biopsy market is growing at over 30% for the company, with significant opportunities in cancer testing and prenatal analysis [21] - QuantiFERON continues to be a strong performer with a cumulative revenue of $2.5 billion, and 60% of the market remains untapped, presenting further growth opportunities [26] Company Strategy and Development Direction - The company is focused on strategic acquisitions and share buybacks, indicating a balanced approach to capital allocation [3] - The acquisition of Parse Biosciences is seen as a strategic fit to enhance the sample prep business and leverage unique features for growth [9] - The company aims to maintain its current strategy despite the CEO transition, emphasizing strong execution and continuity [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for the upcoming year, despite some volatility in the market, particularly regarding the NIH budget and China [58] - The company is cautious about instrument placements due to budget constraints but remains confident in its consumables business [46][56] - Management believes that margin improvements will continue, with a target EBIT margin of at least 31% by 2028 [61] Other Important Information - The company is transitioning its bioinformatics business to a SaaS model, which is expected to stabilize revenue streams and provide growth opportunities [51] - The company has launched new instruments, including the QIAsymphony and QIAsprint, which are expected to contribute to future growth [19][23] Q&A Session Summary Question: What is the outlook for QuantiFERON's growth? - QuantiFERON is expected to continue its double-digit growth, with a significant portion of the market still untapped, presenting opportunities for expansion [26][30] Question: How is the competitive landscape evolving? - The company remains confident in its competitive position, having entered long-term contracts with customers and maintaining a strong market presence despite competition [33] Question: What are the expectations for the new product launches? - New products are anticipated to contribute positively to growth, particularly in high-growth areas like liquid biopsy and sample prep [20][24]

Financial Data and Key Metrics Changes - The company reported a strong performance with a growth rate of 7% in Q1 and 6% in Q2, outperforming the industry [2] - A $500 million share buyback was announced to be executed early next year, increasing from previous years' buybacks of $300 million [3] Business Line Data and Key Metrics Changes - The sample prep business showed improvement, with a growth of 3% in Q3 after being slightly negative in Q1 and slightly positive in Q2 [18] - The consumables business, which constitutes 80-85% of sample prep, demonstrated resilience during market volatility [18] - Parse Biosciences is expected to generate $20 million in revenues in 2024 and around $60 million in subsequent years, contributing positively to the overall margin structure [9][25] Market Data and Key Metrics Changes - The liquid biopsy market is growing at over 30%, with the company positioned to support key players in this space [22] - QuantiFERON continues to show double-digit growth, with significant opportunities remaining in the market as 60% is still served by a traditional skin test [27][32] Company Strategy and Development Direction - The company is focused on strategic acquisitions and share buybacks, indicating a balanced approach to capital allocation [3] - The transition to a SaaS model in the bioinformatics segment is ongoing, with expectations of stable low double-digit growth despite the transition [56] - The company aims to improve its EBIT margin to at least 31% by 2028, with ongoing margin improvement strategies in place [66] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for the upcoming year, despite some volatility in the market, particularly regarding the NIH budget and China [64] - The company is cautious about immediate instrument placements due to budget constraints but remains confident in its overall growth trajectory [62][65] Other Important Information - The company is launching three significant instrumentation products, including the QIAsprint Connect, which is expected to enhance revenue opportunities [19] - The competitive landscape remains stable, with the company maintaining long-term contracts and price increases, indicating confidence in its market position [34][35] Q&A Session Summary Question: Can you elaborate on the CEO transition and its impact? - The board is taking time to find a suitable candidate for the CEO position, with no expected changes in strategy during this transition [6] Question: What attracted the company to Parse Biosciences? - Parse fits well within the sample prep business and is expected to contribute significantly to growth and profitability [9] Question: How is the company addressing the competitive landscape? - The company is confident in its position, having entered long-term contracts and maintained competitive pricing [34][35] Question: What are the expectations for QuantiFERON's growth? - The company anticipates continued double-digit growth, with significant market opportunities remaining [32] Question: How is the company managing its capital allocation? - The company plans to balance share repurchases with potential acquisitions, supported by strong cash flow generation [69]

Financial Data and Key Metrics Changes - The company reported a strong performance with a growth rate of 7% in Q1 and 6% in Q2, outperforming the industry [4] - A $500 million share buyback was announced to be executed early next year, increasing from previous years' buybacks of $300 million [5] Business Line Data and Key Metrics Changes - The sample prep business showed improvement, with a growth of 3% in Q3 after being slightly negative in Q1 and slightly positive in Q2 [19] - The liquid biopsy segment is growing at over 30%, indicating a strong market presence and innovation in cancer testing [23] - QuantiFERON continues to be a durable double-digit grower, with significant market opportunities remaining [28] Market Data and Key Metrics Changes - The company has a significant footprint in the pharma environment, with top pharma customers adopting their solutions [16] - The competitive landscape remains stable, with the company maintaining long-term contracts and price increases despite competition [35] Company Strategy and Development Direction - The acquisition of Parse Biosciences is seen as a strategic move to enhance the sample prep business and drive future growth [11] - The company is focused on transitioning to a SaaS model in its bioinformatics business, which is expected to stabilize revenue streams [53] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for the upcoming year, despite some volatility in the market, particularly regarding the NIH budget situation in the U.S. [60] - The company aims to maintain or improve margins, with a target EBIT margin of at least 31% by 2028 [63] Other Important Information - The company is launching several new instruments, including the QIAsprint Connect, which is expected to drive incremental revenue opportunities [20] - The transition to a SaaS model is ongoing, with expectations of low double-digit growth in the bioinformatics segment [56] Q&A Session Summary Question: What is the outlook for QuantiFERON's growth? - QuantiFERON is expected to continue its double-digit growth, with significant market opportunities remaining, particularly in mandatory testing [28][32] Question: How is the competitive landscape evolving? - The company remains confident in its position, with long-term contracts and price increases indicating strong customer relationships [35] Question: What are the expectations for new product launches? - New products, including QIAsprint and QIAmini, are expected to contribute to growth, particularly in high-growth areas like liquid biopsy [24][26]

Summary of Qiagen's Q3 Conference Call Company Overview - **Company**: Qiagen - **Industry**: Life Sciences, specifically focusing on sample preparation and molecular diagnostics Key Points and Arguments Financial Performance - Qiagen reported a **6% core growth** in Q3, which was better than expectations [1][2] - Growth rates for the year were **7% in Q1**, **6% in Q2**, and **6% in Q3** despite a challenging market environment [2] - The sample preparation business saw an underlying acceleration to **3% growth**, which is significant ahead of upcoming major instrumentation launches [3] Market Challenges - The company is facing challenges due to the **US government shutdown** and funding uncertainties, particularly affecting the academic environment [4][5] - The funding situation remains unclear, impacting long-term investment confidence in new instrumentation [6][8] - The instrumentation segment, which constitutes about **10% of the business**, is expected to take time to normalize due to funding perceptions [8][9] Margin and Guidance - Qiagen's operating margin guidance for the year is between **29% and 30%**, with an expected end at **29.5%**, reflecting a **300 basis points improvement** over the last three years [11] - The company anticipates further margin expansion in the midterm, targeting **31% by 2028** [12][13] - Headwinds include **dilution from acquisitions** and **currency impacts**, but operational improvements are expected to offset these challenges [12] Product Development and Innovation - Qiagen is launching new products, including the **Qiagen Sprint** for high-throughput sample prep and the **Qiagen Symphony Connect** platform, which aims to enhance workflow and integration [25][26] - The company is also introducing the **Qiagen Mini**, a cost-effective solution for sample prep in academic settings [28] - The focus on **digital PCR** is highlighted as a growth driver, with opportunities in **companion diagnostics** and **pharma** [35][36] Strategic Acquisitions - Qiagen's acquisition of **Parse** is seen as a strategic move to enhance its offerings in the single-cell market, with expected revenues from Parse projected to double from **$20 million to at least $40 million** next year [18][19] - The integration of Parse's technology is expected to create synergies with Qiagen's existing customer base, particularly in the academic and pharma sectors [20][22] Market Position and Future Outlook - Qiagen aims to diversify its product offerings beyond respiratory diagnostics, with significant growth in **gastrointestinal** and **meningitis** testing [30][32] - The company is optimistic about returning to a **3-4% CAGR by 2028**, driven by new product launches and market expansion [24] - The normalization of the academic environment is expected to boost sample prep sales, with a focus on maintaining a broad menu of diagnostic options [34] Bioinformatics and SaaS Transition - Qiagen's bioinformatics segment is experiencing double-digit growth, transitioning to a **SaaS business model** which may impact revenue recognition in the short term [39][40] - The acquisition of **Genox** is expected to enhance Qiagen's reach into smaller accounts, contributing to continued growth in this segment [40] Additional Important Insights - The company is leveraging digital channels for sales, with **60% of revenues** currently coming through these channels, aiming to increase this to **75%** [16] - There are ongoing cost-out programs focused on improving gross margins and operational efficiencies [14][15] This summary encapsulates the key insights from Qiagen's Q3 conference call, highlighting the company's performance, challenges, strategic initiatives, and future outlook in the life sciences industry.